Contact
searchSearch
HMP Global
Login

Real-World Data Topic Center

Scott Swain, PhD.
Videos
Navigating the FDA’s Guidance on Real-World Evidence: Insights, Expectations, and Future Trends in Clinical Trials
02/02/2024
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director...
02/02/2024
Journal of Clinical Pathways
Conference Coverage
The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration
12/06/2023
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world...
12/06/2023
Journal of Clinical Pathways
Video thumbnail screenshot.
Videos
Using Digital Health to Implement Patient-Reported Outcomes in Cancer Care
08/30/2023
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns...
08/30/2023
Journal of Clinical Pathways
Christopher D'Avella, MD.
Videos
Using Provider Feedback to Improve Efficiency and Utilization of the Flatiron Assist EMR-Based Pathways Tool
08/14/2023
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks...
08/14/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways
Smita Agrawal, PhD.
Videos
Enhancing Line of Therapy Derivation Using Real-World Data From Electronic Health Records Via Integration of Medical Claims Data
08/08/2023
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive...
08/08/2023
Journal of Clinical Pathways
News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
Conference Coverage
Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma
12/10/2022
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
OCPC: In Session
Highlights of the 2022 Clinical Pathways Benchmark Survey
12/05/2022
Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.
Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.
Winston Wong, PharmD,...
12/05/2022
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma
06/15/2022
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates...
06/15/2022
Journal of Clinical Pathways

Expert Insights

Scott Swain, PhD.
Videos
Navigating the FDA’s Guidance on Real-World Evidence: Insights, Expectations, and Future Trends in Clinical Trials
02/02/2024
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director...
02/02/2024
Journal of Clinical Pathways
Video thumbnail screenshot.
Videos
Using Digital Health to Implement Patient-Reported Outcomes in Cancer Care
08/30/2023
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns...
08/30/2023
Journal of Clinical Pathways
Christopher D'Avella, MD.
Videos
Using Provider Feedback to Improve Efficiency and Utilization of the Flatiron Assist EMR-Based Pathways Tool
08/14/2023
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks...
08/14/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways
Smita Agrawal, PhD.
Videos
Enhancing Line of Therapy Derivation Using Real-World Data From Electronic Health Records Via Integration of Medical Claims Data
08/08/2023
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive...
08/08/2023
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma
06/15/2022
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates...
06/15/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Ethan Sokol, PhD
Videos
Real-World Outcomes of HR-Positive HER2-Negative Metastatic Breast Cancer Treated With ICIs
10/21/2021
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses...
10/21/2021
Journal of Clinical Pathways
Geoffrey Oxnard, MD
Videos
Real-World Testing and Treatment Patterns in Advanced NSCLC
10/18/2021
Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.
Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.
Geoffrey Oxnard, MD, compares...
10/18/2021
Journal of Clinical Pathways
Weija Wang
Videos
Real-World Outcomes of Febrile Neutropenia Among Patients With Breast Cancer or Non-Hodgkin Lymphoma
05/27/2021
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses...
05/27/2021
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Videos
Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams
11/12/2024
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...
Shaffee Bacchus, PharmD,...
11/12/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up
11/08/2024
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...
Kerry Rogers, MD, provides a...
11/08/2024
Journal of Clinical Pathways
BDHC Thumbnail
Breaking Down Health Care
Navigating Payer Challenges in Cell and Gene Therapy
11/07/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the challenges and potential solutions for integrating cell and gene therapies—particularly CAR T—into clinical practice and insurance...
In this Breaking Down Health...
11/07/2024
Cancer Care Business Exchange
Videos
Navigating Multidisciplinary Care: Insights on Oncology Practice Integration and Pharmaceutical Partnerships
11/04/2024
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at Valuate Health Consultancy, highlights the importance of multidisciplinary collaboration in oncology care to improve patient outcomes.
John Hennessy, Principal at...
11/04/2024
Journal of Clinical Pathways
Videos
Custom Pathways in Oncology: Innovations, Stakeholder Collaboration, and Value-Based Care
11/01/2024
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron Health, highlights the importance of custom oncology pathways in enabling real-time updates for oncologists, fostering collaborative implementation teams, and supporting...
James Hamrick, MD, MPH, Vice...
11/01/2024
Journal of Clinical Pathways
Interview
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
10/30/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
10/30/2024
Journal of Clinical Pathways
JB
Interview
The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care
10/25/2024
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.
Learn about recent advancements...
10/25/2024
Journal of Clinical Pathways
Jessica Paulus, ScD
Interview
Insights on Lung Cancer Diagnosis Trends and Screening Challenges in Community Oncology
10/23/2024
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica Paulus, ScD, senior director of real-world research at Ontada, discusses trends in advanced non–small cell and small cell lung cancer diagnoses, the impact of the COVID-19 pandemic on screening, and the need for...
In this interview, Jessica...
10/23/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology

Newsfeed

News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
Conference Coverage
Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma
12/10/2022
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
News
Real-World Risk of Infusion Reactions and Efficacy of Frontline Obinutuzumab-Chlorambucil for CLL
02/10/2022
Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.
Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.
Study findings suggest risk of...
02/10/2022
Journal of Clinical Pathways
News
Real-World Utilization of and Spending on New Targeted Cancer Drugs in the United States
11/03/2021
A real-world study suggests that cancer drugs without documented OS benefits are increasingly adopted in the health system, accounting for substantial spending.
A real-world study suggests that cancer drugs without documented OS benefits are increasingly adopted in the health system, accounting for substantial spending.
A real-world study suggests that...
11/03/2021
Journal of Clinical Pathways
News
Maintenance Therapy Patterns for Recurrent Ovarian Cancer in Real-World Setting
08/04/2021
Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.
Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.
Findings from a real-world...
08/04/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways
News
Real-World Impact of Baseline Risk Factors on Incidence of Febrile Neutropenia in Patients With Breast Cancer
07/28/2021
Findings from a real-world study show the choice of febrile neutropenia definition significantly changed the impact of risk factors on febrile neutropenia outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim...
Findings from a real-world study show the choice of febrile neutropenia definition significantly changed the impact of risk factors on febrile neutropenia outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim...
Findings from a real-world study...
07/28/2021
Journal of Clinical Pathways
News
Real-World Health Care Utilization and Costs in the Huntsman at Home Program
06/02/2021
A recent study found that an oncology hospital at home program model may lower unplanned health care utilization and health care costs for patients with cancer.
A recent study found that an oncology hospital at home program model may lower unplanned health care utilization and health care costs for patients with cancer.
A recent study found that an...
06/02/2021
Journal of Clinical Pathways
News
Real-World Treatment Discontinuation Among Patients With CLL
05/13/2021
05/13/2021
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
Harnessing the Potential of Abemaciclib in Recurrent Endometrial Cancer Treatment
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
Pembrolizumab Plus Adjuvant Chemotherapy for Newly Diagnosed High-Risk dMMR Endometrial Cancer
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
False Negatives More Prevalent in Endometrial Cancer Screening for Black Women
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
Efficacy of Momelotinib in Managing Anemia in Myelofibrosis: Results from the SIMPLIFY-2 Trial
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

Interactive Features

SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Scott Swain, PhD.
Videos
Navigating the FDA’s Guidance on Real-World Evidence: Insights, Expectations, and Future Trends in Clinical Trials
02/02/2024
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director...
02/02/2024
Journal of Clinical Pathways
Conference Coverage
The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration
12/06/2023
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world...
12/06/2023
Journal of Clinical Pathways
Video thumbnail screenshot.
Videos
Using Digital Health to Implement Patient-Reported Outcomes in Cancer Care
08/30/2023
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns...
08/30/2023
Journal of Clinical Pathways
Christopher D'Avella, MD.
Videos
Using Provider Feedback to Improve Efficiency and Utilization of the Flatiron Assist EMR-Based Pathways Tool
08/14/2023
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks...
08/14/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use